CCRN Cardiac
CCRN Cardiac
Remember:
The cardiac muscle gets its perfusion during diastole.
Perfusion is determined by coronary perfusion pressure
Coronary Perfusion Pressure = Diastolic BP PCWP
3
Normal: 60 -80 mmHg
Hemodynamics
Cardiac Output = HR x Stroke Volume (SV)
Preload
Afterload
Cardiac Output
Stroke Volume
Contractility
Muscle Synchrony
5
4/6/2013
Preload
The force on the ventricle during relaxation (diastole)
Primary determinant is the volume of blood filling the
ventricle
Right Ventricle = RVEDP (Right heart preload):
Right Atrial Pressure (RAP); CVP
Normal values: 2-6mmHg
Contractility
Afterload
Cardiac Index
10
Supply
&
Demand
tissue
Heart rate
Preload
Afterload
Contractility
Oxygen Demand
Oxygen Supply
CO
BSA
11
Heart
12
4/6/2013
SVO2
SVO2 amount of oxygen in the mixed
SaO2
O2 Tissue
Consumption
CO
Hgb
13
Oxygen Delivery
Question
SvO2 = 75%
SaO2 = 100%
Venous
Return
Oxygen
Consumption
14
25%
Arterial
Oxygen
Delivery
The Cell
15
Cardiac Assessment
16
Arterial Waveform
Hemodynamic Monitoring
ECG Interpretation
Diastole (C)
Lowest portion of waveform
Normal 60-90
Dicrotic Notch (B)
Closure of Aortic valve
Heart Sounds
17
A
B
C
18
4/6/2013
19
Preload
What Decreases:
Hypovolemia
Position Change
Vasodilation
Right Heart Damage
Atrial Arrhythmias
Pericardial Effusion
20
CVP waveform
Pressure measurement is taken from
What Increases:
Vasoconstriction
fluid volume
ventricular filling
time
Bradycardia
PEEP
Tension
Pneumothorax
21
22
Normal RV:
Sys: 15-30
Dia: 2-6 mmHG
23
24
4/6/2013
Phlebostatic axis
Normal PCWP:
4 12 mmHG
in a lateral position.
Allow 5 minutes for stabilization after changing the
patients position
26
Technical Factor:
Mechanical Ventilation
Technical Factors:
Effect of Patient Respirations
If the patient is on a mechanical ventilator, the
positive pressure pushes up the PA tracing.
Ventilator Valleys
A PEEP > 10 will artificially elevate PA pressures
If patient is breathing spontaneously, the negative
pressure pulls down the PA tracing. Spontaneous
sky
Technical Factor:
Spontaneous Respirations
28
Afterload
29
BP = 120/80 (93)
CVP = 5
CO = 5
SVR = [(93 5) / 5] x 80 = 1406
30
4/6/2013
ECG Monitoring
Conduction System
32
Refractory Period
33
Question
The cardiac monitor shows the rhythm below
for your patient. Which of the following
medications might the physician order?
a. Atropine
b. Adenocard
c. Cardizem
d. Amiodarone
36
4/6/2013
Amiodarone
Dosage:
Non-VT/V.fib: 150 mg IV over 10 min.
Pulseless VT/V.fib: 300mg IV bolus
a. Depressed ST segment
b. Tall, tented T waves
Adverse effects:
Hypotension and bradycardia are common
during initial bolus.
May be prevented by slowing the rate of
infusion.
c.
Prolonged QT interval
d. u-wave
37
38
Too Fast
Administration:
Bolus: 1.0-1.5 mg/kg IVP; may repeat in 5-10
tremors.
39
Sinus Tachycardia
40
Supraventricular Tachycardia
in CO
Significance:
Must treat if prolonged
41
42
4/6/2013
Atrial Flutter
SVT Treatment
Significance:
Consider this a hazardous rhythm because it can
suddenly change to a rapid ventricular response.
43
44
Atrial Fibrillation
Question
Lidocaine
Cardizem
Corvert
Adenocard
45
46
To Control Rate,
Use Selective - Blockers
Non-Selective:
Propranolol (Inderal)
Nadolol (Corgard)
Selective agents:
Beta Blockers
Calcium Channel Blockers
Amiodarone *
Atenolol (Tenormin)
Betaxolol (Zebeta)
Metoprolol (Lopressor)
Vasodilatory, Non-selective
Labetalol (Normodyne)
Carvedilol (Coreg)
Shortest half-life:
Esmolol
47
48
4/6/2013
Ventricular Tachycardia
To Control Rate:
Use Calcium Channel Blockers
Significance:
Treatment is REQUIRED
Pulse or NO Pulse?
Pulse & STABLE? Use AMIODARONE
Pulse & UNSTABLE
ELECTRICAL CARDIOVERSION
Example: Diltiazem
Do not use in:
Drug-induced tachycardia
Heart blocks
Concurrent use of Beta blockers.
49
Question
50
Electrical Cardioversion
51
Synchronized Cardioversion:
Energy Selection
52
Synchronized Cardioversion:
Energy Selection
If the rhythm does not change, recharge to 200 joules
& repeat
54
4/6/2013
Synchronized Cardioversion:
Pre-Medication
Too Slow
Diazepam
Midazolam
Etomidate
Analgesics
Fentanyl
Morphine
Merperidine
3Heart Block
Sinus Bradycardia
Characteristics:
HR > 60
All intervals within
normal limits
except rate
56
Significance:
PREPARE TO PACE!
May be normal in
New guidelines:
chronotropic drips
healthy, young
patient.
Treat symptomatic
bradycardias!
57
58
Temporary Pacemakers
Symptomatic Bradycardia
Treat Bradycardia with BRADE
Transcutaneous
Dopamine: 2 to 10 mcg/kg/min
Transvenous
Epicardial
59
60
10
4/6/2013
Transcutaneous Pacemaker
Transvenous Pacemaker
Epicardial Pacemaker
Temporary
Generator
Epicardial Pacemaker
Lead Placement
Transvenous Pacemaker
Lead Placement
61
62
External Pacing
Position
Category Chamber(s)
Paced
II
III
IV
Chamber(s)
Sensed
Response to
Sensing
Programmability
Rate Modulation
Antitachyarrhythmia
Function(s)
O = None
O = None
O = None
O = None
O = None
A = Atrium
A = Atrium
T = Triggered
P = Simple Programmable
P = Pacing
V = Ventricle
V = Ventricle
I = Inhibited
M = Multiprogrammable
S = Shock
D = Dual (A+V)
D = Dual (A+V)
D = Dual (T+I)
C = Communicating
D = Dual (P+S)
R = Rate Modulation
Manufacturers
Designation
Only
63
S = Single
(A or V)
S = Single
(A or V)
64
Sensitivity
Pacing Codes
VVI
the number,
sensitivity(more sensitive)
65
5.0v
2.8v
1.4v
66
11
4/6/2013
Loss of Capture
Troubleshooting
Failure to capture
Improper Sensing
Loss of Output
Atrial
No capture
Ventricular
No capture
Fusion
67
68
Undersensing
Failure to Capture
Undersensing: Causes
70
Undersensing
Battery depletion
Decreased QRS voltage
Fusion beat
Dislodged/fractured lead
Inappropriate sensitivity setting
What to do:
Increase the sensitivity by
lowering the number
(lower the fence)
71
72
12
4/6/2013
Oversensing
Oversensing
What to do:
Eliminate interference
Adjust sensitivity: Make less sensitive by
increasing the number (raise the fence)
No Output
74
OH, NO!
Oversensing
Dislodged/fractured lead
75
Ventricular Fibrillation
76
Defibrillation
Energy Requirements for adults:
If using a biphasic defibrillator:
150- 200 joules initially
For second and subsequent shocks, use
the same energy or higher
If using a monophasic defibrilators:
Select a dose of 360 joules for all shocks
Significance:
Requires immediate defibrillation & CPR!
77
78
13
4/6/2013
Epinephrine:
Epinephrine
improve survival
responsive to defibrillation
79
80
Vasopressin
A PULSE.
Characteristics: Variable
Significance:
Effects:
81
Asystole
82
84
14
4/6/2013
Therapeutic Hypothermia
Recommended for
witnessed pulseless VT &
VF arrests
Ts:
Toxins,
Tamponade,
Tension pneumothorax,
Thrombosis (cardiac and
pulmonary),
Trauma
Tablet (overdose)
May be beneficial in
PEA/Asystole arrests
Potential complications
Infection
Bradycardia
Electrolyte imbalances
Potassium
Calcium
Phosphorus
Magnesium
Hyperglycemia
85
Heart Sounds
S3: ventricular gallop
Normal in children
Adults: LVEDP
(preload); LV failure
Summation gallop
S4, S1,S2, S3
CHF, anemia,
ischemic hearts
86
Systolic murmurs
Aortic stenosis
Pulmonic stenosis
Mitral insufficiency
Tricuspid
insufficiency
Diastolic murmurs
Aortic insufficiency
Pulmonic
insufficiency
Mitral stenosis
Tricuspid stenosis
87
88
Risk Factors
Cigarette smoking
Hypertension
Obesity
Diabetes Mellitus
Gender/Age
DBP > 95 mm Hg
Sedentary lifestyle
Hyperlipidemia
Total chol >240
mg/dL
Family history
90
15
4/6/2013
Classification of Infarct
Coronary Arteries
TIME IS MUSCLE
Left anterior
descending (LAD)
Circumflex (CF)
91
Right Coronary
Artery
RA & RV muscle
92
Bundle of His
Anterior 2/3
Inferiorposterior wall of LV
intraventricular septum
R bundle branch
94
Left Circumflex
Asymmetry
The T wave is normally positive in leads I, II, V3 to V6
The T wave is less than 2/3 the height of the preceding
R wave.
95
96
16
4/6/2013
T waves that are tall and peaked suggest elevated potassium levels
97
The ST segment
baseline
Normal ST
Segment
Elevated ST
Segment
98
Depressed
ST Segment
ST Depression
100
17
4/6/2013
ST Elevation
Q Waves: Infarction
Pathological Q wave represents an area of dead
tissue or infarction.
The Q wave is > 0.04 seconds wide
The Q wave is >1/4 of the height of the R wave
that follows.
Q waves usually take up 24 hours to develop.
They do not reveal when the infarction
occurred.
Early development of Q waves predicts a
large infarction.
103
Pathologic Q Waves
104
Cardiac Markers
CPK 3 isoenzymes
CPK-MB is more specific to myocardium. Normal values:
CK (Total) - Males < 180, Females <130
CK MB Mass - < 8.0
CK Relative Index - < 4.0
Can be falsely elevated in renal failure, skeletal muscle injury,
marathon runners
Elevations do not occur for up to 6 hours after injury.
Troponin I
Elevations start within 3 hours after ischemic event.
Normal value: < 0.6
Remains elevated longer than CPK -MB
Highly sensitive markers for cardiac injury
105
Case Study
106
Risk Stratification
Initial Interventions
(within 10 minutes)
Targeted history
Biomarker
1230
1900
0445
<0.04
245.4
258.35
3792
3487
493.8
330.5
Troponin I
CK
CK-MB
2.8
Vital signs
Serum Markers
Goal:
MONA
107
108
18
4/6/2013
109
110
High Lateral
High Lateral
Inferior
Lateral
AVR None
V1 Septal
V4 Anterior
II Inferior
AVL Lateral
V2 Septal
V5 Lateral
III Inferior
AVF Inferior
V3 Anterior
V6 Lateral
Septal
Anterior
Low Lateral
Localizing Injury
Affected
Part
Vessel(s)
Involved
Leads
Anterior
LAD
V3, V4
Inferior
RCA
Lateral
Septal
Circumflex
LAD
Posterior
Circumflex; Reciprocal
RCA
changes, V1, V2
Right
RCA
Ventricular
112
TREATMENT
Electrical Complications
PVC, SVT, 2 AV Mobitz II,
CHB, BBB, Hemiblocks
PVC, SB, ST, JR, PAC, Atrial
Fib, 2 AV Mobitz II
(Wenckeback)
PVC, SB, ST, PAC, A. Fib
Same as Anterior
Same as Inferior
V4R
113
114
19
4/6/2013
Treatment
STEMI
Non-STEMI
NO
YES
Reperfusion:
Door to needle: < 30 min
Door to balloon: < 90 min
NTG
Beta Blockers
ACE Inhibitors
Statin Therapy
Heparin
Clopidogrel
Non-Diagnostic
NTG
Beta Blockers
ACE Inhibitors
Statin Therapy
Heparin
Glycoprotein
IIB/IIIA Inhibitor
Clopidogrel
Oxygen:
Continue for at least
initial 6 hours, then
DC if oxygen
saturation is >90%.
Nitroglycerin: Dilates
Aspirin: Inhibits
platelet aggregation.
Give 162- 325 mg as
soon as patient
arrives in ED.
CHEW.
115
Question
116
117
118
Adjunctive Medications
If a Blockage is found:
Multiple options are available
Balloon angioplasty
Coronary atherectomy
Stent placement
Laser
Prasugrel (Effient)
Heparin, Lovenox
ACE Inhibitors & ARBs
Statins
119
120
20
4/6/2013
Blockers
Blockers
Mechanism of action:
Blocks catecholamines
Absolute
Contraindications
Severe CHF
SBP < 100 mm HG
Acute asthma
2nd or 3rd degree heart block
Cautions
Mild / moderate CHF
Heart rate <60
History of asthma
Insulin dependent
diabetes
Severe Peripheral
Vascular Disease
121
122
Glycoprotein IIB/IIIC
Clopidogrel (Plavix):
Inhibitors
Irreversible inhibition of
platelet aggregates
time of reperfusion,
continue 75 mg daily
dose for 8 days.
May need to withhold
for 5 7 days prior to
CABG
124
ACE Inhibitors
Mechanism of action
JG cells
stimulated
Renin
released
Reaction with
angiotensinogen
converting enzyme
Alters left ventricular remodeling that occurs
Increased
blood vol.
Improved renal
blood flow
125
Na+, H2O
retention
Aldosterone
secretion
Increased arterial
blood pressure
Angiotensin I then
II production
Vasoconstriction
126
21
4/6/2013
MI Complications
Statins
complications such as reinfarction, recurrent
angina, and arrhythmias
Dysrhythmias most
common complication
of the deaths occur within
127
Question
Your MI patient suddenly develops LOC, a weak, thready
pulse, and bilateral posterior crackles in the lower lung fields.
VS: 78/46; HR 139; RR 25
u/o < 30 ml for the last hour
O2 sat 89% on 4L NC
You suspect
RV infarction:
posterior MI. Incidence
around 40%
Patients with RV infarct
need VOLUME & are
very sensitive to NTG
Emboli:
Thrombi form on inner
Papillary muscle
rupture
128
a. Stroke
b. ARDS
c.
Pulmonary embolus
d. Cardiogenic shock
129
IABP Placement
130
132
22
4/6/2013
Supply
Deflation immediately
prior to systole
Aortic end-diastolic
Demand
pressure
Impedance to ejection
Afterload
Oxygen demand
Indications
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
134
Contraindications
Cardiogenic shock
Refractory ventricular failure
Unstable refractory angina / impending infarction
Mechanical complications due to acute myocardial
infarction
Ischemia related to intractable ventricular
arrhythmias
Cardiac support for high risk general surgical and
coronary angiography / angioplasty patients
Septic shock
Weaning from cardiopulmonary bypass
Intra-operative pulsatile flow generation
Support for failed angioplasty and valvuloplasty
Question
136
LV filling volume
d. LV systolic pressure
137
138
23
4/6/2013
Pathophysiology:
Systolic Dysfunction
Impaired LV contractility results in
Dilated Heart
(Systolic Failure)
Etiology:
Acute Myocardial Infarction
Coronary Artery Disease,
Hypertension
Valvular Heart Disease
Toxins
Endocrine
Congenital
Myocardial Toxicity
Morbidity
Mortality
Hypertrophic Heart
(Diastolic Failure)
Sarcoidosis
Amyloidosis
140
Forward Failure
BNP
ANP
Peripheral vasoconstriction
Hemodynamic alterations
Remodeling and
progressive
worsening LV function
Fall in LV Performance
139
Myocardial
Injury
Pathophysiology:
Diastolic Dysfunction
Signs of Decreased CO
Fatigue, poor exercise
tolerance
Tachycardia
Narrow pulse pressure
Cool, pale, diaphoretic
Altered mental status
Decreased urine output
Backward Failure
Signs of Elevated
Pulmonary Pressure
Dyspnea, tachypnea
Orthopnea
Cough, wheeze
Hypoxia
Respiratory Alkalosis
Crackles, rhonchi
S3,S4
141
142
What kind of
heart failure
does this man
have
Right or Left ?
RAP/CVP
Fluid vol. Backs into portal system
GI s/s
Ascites
Nocturia
Weakness, fatigue
Murmur of TR
143
144
24
4/6/2013
A
B
II
III
IV
Compensatory Mechanisms
None
146
VENTRICULAR REMODELING
Myocardial Hypertrophy
Decrease contractilitydecreased stroke
volumeActivation of SNS & RAAS
Increased ventricular volumes
HEART FAILURE
147
148
Pharmacologic
Pillars of Treatment:
Systolic Treatment
Loop diuretics
Spironolactone
Diastolic Treatment
Beta Blockers
Diuretics
ACE inhibitors
Beta Blockers
Contractility: Digitalis
Digoxin
ACE inhibitors
Calcium Channel
Diuretics, VasoDILATORS:
Blockers
149
150
25
4/6/2013
several weeks.
Selective agents incidence
of:
Bronchospasm
Cold extremities
Other peripheral side effects
151
Preload: Diuretics
GOAL: To restore fluid balance
Beneficial effects
Excrete sodium and water
Decrease CVP
Symptom relief
Decrease shortness of
breath & edema
152
Detrimental effects
Electrolyte imbalances
Decrease renal
function
Activates RAAS
Hypotension
Contractility
Nitrates not as
Effective as ACE
Inhibitors
154
occurring molecules.
Actions:
tolerance to dobutamine
155
156
26
4/6/2013
BNP Measurement
Natrecor (Nesiritide)
157
158
Adjunct Therapies
Beta blockers
ACE
Statins Believed to decrease inflammatory response
Physical conditioning
Consider:
160
Question
Heart Transplant
162
27
4/6/2013
Question
Myocarditis
Endocarditis
Pericarditis
163
Myocarditis
164
Question
b. Furosemide 40 mg IV
c.
Ibuprofen 800 mg PO
d. Morphine sulphate 2 mg IV
165
Infective Endocarditis
166
Question
Etiology:
Congenital or acquired heart disease
Invasive monitoring (PA catheters,
167
168
28
4/6/2013
Infective Endocarditis:
Presentation
Janeway
lesions
Infectious Endocarditis
Diagnosis: Blood cultures; TEE
Management
Prevention:
Patients with valve disease should receive antibiotics prior to any
invasive procedure
Good hygiene
No street drugs
Decrease myocardial oxygen demand
Control and treat infection
Antibiotics for 6 8 weeks
Monitor for complications
Systemic emboli
Valve surgery may be required
toes
Oslers
Nodes
169
Pericarditis
Pericarditis
Etiology:
Presentation:
Sharp, stabbing pain that radiates to the left
shoulder
Aggravated by inspiration, supine position
Relieved by sitting up or leaning forward
Dyspnea, tachypnea
Tachycardia
Murmur / rub
Fever
Diagnostic:
Idiopathic
Post MI May be acute
170
(within 7 days) or
Dresslers syndrome
(occurs 2 wks or more
later)
Trauma
Infection
Radiation
Drugs
Definition:
Inflammatory process involving the
visceral or parietal pericardium
Pericarditis - Management
Cardiac Tamponade
Management
Non-steroidal anti-inflammatory drugs
Treat cause
Monitor for complications:
172
TAMPONADE
Dysrhythmias
window
173
174
29
4/6/2013
Hypertension Definitions
Question
176
Hypertensive Crisis
Principles of Treatment
BP = CO x PVR
next 24 hours
Agents:
Sodium nitroprusside, fenoldopam, hydralazine
Hydralazine good in eclampsia
177
Question
178
Cardiomyopathy
Dilated
Hypertrophic (Idiopahtic
179
180
30
4/6/2013
Cardiomyopathy: Dilated
Cardiomyopathy: Hypertrophic
mass & thickening of myocardium
Fibrosis occurs
LV chamber in size
181
182
Cardiomyopathy: Restrictive
Restricted filling of ventricles
Etiology: Idiopathic; Amyloidosis
LVEDP ; contractility ; CO HF
Death
183
Cardiomyopathy: Rx
ACE inhibitors
B-blockers
Antidysrhythmic
agents
Antibiotics (at risk for
infectious
endocarditis)
184
DCM: + inotropes;
diuretics
HOCM: Avoid agents
that preload; avoid +
inotropes (can worsen
obstruction)
Saphenous veins
Radial artery
Gastroepiploic artery
Inferior epigastric artery
185
186
31
4/6/2013
Question
Question
187
188
Valve Surgery
The primary cause for valve disease is
rheumatic fever.
Most commonly affected the aortic and
a. Ace-inhibitor
b. Beta-blocker
mitral valves
If allowed to persist, congestive heart
Cardiac Trauma
190
Question
192
32
4/6/2013
Aortic Aneurysms
Thoracic or Abdominal.
Abdominal are more common (65%)
Two patterns:
a. Back pain
c. Intermittent claudication
asymptomatic
Rupture of the aneurysm causes acute
pain that radiates to the back,
unrelieved by changes in position.
Mortality from rupture is 90%. The
only chance for survival is emergent
repair.
193
Aortic Dissection
194
Question
195
196
Question
On PO day 2 after an AAA, your patient develops
hypotension, tachycardia, abdominal
distention, and WBC. These findings
indicate
a. Post-op graft infection
b. Ischemic colitis
c. Aortic-enteric fistula
d. Abdominal compartment syndrome
197
198
33
4/6/2013
Question
After aorto-femoral
bypass surgery for
acute arterial
occlusion, your
patient has
CPK, K+ 5.9 mE/L
PaO2 90
PaCO2 24
HCO3 19
Dysrhythmias
Graft occlusion
Pulmonary embolus
Heart Failure
199
Question
Question
A patient is receiving thrombolytics via
continuous infusion for acute limb
ischemia suddenly complains of pain in
the affected extremity. The most
appropriate nursing action includes:
200
pain
the heart
Compartment syndrome
Graft occlusion
Development of false aneurysm
Heparin induced thrombocytopenia (HIT)
compartment syndrome
the MD
201
202
Left-to-right shunt
resulting in right
chamber overload
RA, RV dilate
Valvular disease
Leads to pulmonary
hypertension
Dysrhythmias: Afib,
A.Flutter, PR
prolongation,
Incomplete RBBB. LAD
203
Treatment:
Antibiotics to prevent
endocarditis
Manage heart failure s/s
Surgical repair
204
34
4/6/2013
Valvular Disease
Left-to-right shunt
Mitral Regurgitation
Pulmonary HTN
S/S
Tachypnea
Sweating
Hemoptysis
Heart Failure
Holosystolic murmur
Mitral Stenosis
Treatment
Antibiotics
Manage HF s/s
Surgical repair
Aortic Regurgitation
Aortic Stenosis
205
206
workload LA & LV
Left-sided HF
Tx
Tx
Ab
Ab
Tx HF
Antihypertensives
Surgical Closure
207
208
210
35
4/6/2013
211
212
150mg/dL
213
214
Diastolic pressure
Systolic pressure
Afterload
SVR
a.
b.
c.
d.
215
Variant angina
Stable angina
Unstable angina
Prinzmetals angina
216
36
4/6/2013
a.
c.
217
218
a. Dopamine (Intropin)
b. Captopril (Capoten)
c. Decrease afterload
c. Digoxin (Lanoxin)
d. Procainamide (Pronestyl)
219
220
a.
Sinus bradycardia
Diastolic murmur
Peripheral edema
Bibasilar crackles
b.
c.
d.
221
Increased RAP
Decreased RAP
Increased PCWP
Decreased PCWP
222
37
4/6/2013
a.
b.
c.
d.
c. Ventricular aneurysm
DVI
DDD
VAT
VVI
224
a. Inhibit vasodilation
b. Increase myocardial contractility
c. Increase venous return
d. Reduce myocardial oxygen consumption
225
226
Thanks
Special thanks to
Carol Boswell, RN, MSN, CCRN
for the use of many of her slides in this
presentation.
Brugada syndrome
228
38
4/6/2013
Questions?
Beth Torres, PhD, RN, CCRN
CJW Medical Center,
Chippenham Campus
[email protected]
804-327-4186
229
39